General
Preferred name
PROPOFOL
Synonyms
Diprivan ()
2,6-Diisopropylphenol ()
Disoprofol ()
ICI-35868 ()
Fresofol ()
ICI 35-868 ()
Rapinovet ()
ICI 35,868 ()
Disoprivan ()
Phenol, 2,6-bis(1-methylethyl) ()
Lipuro ()
NSC-5105 ()
Propofol component of ketafol ()
ICI35,868 ()
P&D ID
PD000647
CAS
113981-41-2
2078-54-8
Tags
available
drug
Approved by
FDA
First approval
1989
Drug indication
Leukemia
Anaesthesia
Drug Status
vet_approved
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY
Overdosage may increase pharmacologic and adverse effects or cause death. ;
IV LD50=53 mg/kg (mice), 42 mg/kg (rats). Oral LD50 (as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)
DESCRIPTION
Propofol is a short-acting (lasting 5-10 minutes) sedative.
Propofol is on the World Health Organisation's List of Essential Medicines. Click here to access the pdf version of the WHO's 21st Essential Medicines list (2019). (GtoPdb)
Propofol is on the World Health Organisation's List of Essential Medicines. Click here to access the pdf version of the WHO's 21st Essential Medicines list (2019). (GtoPdb)
DESCRIPTION
Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic[1].
DESCRIPTION
Short acting general anesthetic
(LOPAC library)
DESCRIPTION
Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid through GABA-A receptors.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
1
Compound Sets
25
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
48
Molecular Weight
178.14
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
1
cLogP
3.64
TPSA
20.23
Fraction CSP3
0.5
Chiral centers
0.0
Largest ring
6.0
QED
0.73
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Muscarinic
Member status
virtual
MOA
TRPV1 (Vanilloid VR1 Receptor) Agonists
benzodiazepine receptor agonist
Target
FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A
Endogenous Metabolite
GABA Receptor
Indication
anesthetic
Therapeutic Class
Hypnotics and Sedatives
Pathway
Membrane Transporter/Ion Channel
Metabolic Enzyme/Protease
Neuronal Signaling
Source data
